Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-26, Stock:ABBV, The news for the past five days is as follows:
2019-02-19: NEWS1: Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review.NEWS2: 2 Pharma Stocks in the Middle of an Oncology Sales Explosion.NEWS3: 2 Pharma Stocks in the Middle of an Oncology Sales Explosion.NEWS4: 2 Pharma Stocks in the Middle of an Oncology Sales Explosion.NEWS5: AbbVie stock up 0.2% after FDA grants upadacitinib priority review status.NEWS6: AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis.
2019-02-20: NEWS1: AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review.NEWS2: AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review.NEWS3: AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review.NEWS4: Notable ETF Outflow Detected - IYH, ABT, MDT, ABBV.NEWS5: Notable ETF Outflow Detected - IYH, ABT, MDT, ABBV.NEWS6: U.S. settles with Teva over keeping generic drugs off market.NEWS7: Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review.NEWS8: Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review.
2019-02-21: NEWS1: GILD or ABBV: Which Is Expected to Report Faster EPS Growth?.NEWS2: AbbVie Declares Quarterly Dividend.NEWS3: GILD or ABBV: Which Is Expected to Report Faster Revenue Growth?.NEWS4: What Analysts Are Recommending for GILD and ABBV in February.NEWS5: The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan.NEWS6: Waltham biotech Morphic signs $725M partnership with Janssen.
2019-02-22: NEWS1: Why Voyager Therapeutics Is Skyrocketing Today.NEWS2: Why Voyager Therapeutics Is Skyrocketing Today.NEWS3: Energy Sector Update for 02/22/2019: VYGR, ABBV.NEWS4: Energy Sector Update for 02/22/2019: VYGR, ABBV.NEWS5: Why Voyager Therapeutics Is Skyrocketing Today.NEWS6: Voyager Therapeutics stock jumps on 2nd Parkinson's deal.NEWS7: What Are the Key Growth Catalysts for AbbVie in 2019?.NEWS8: Voyager Shares Take Off on Parkinson's Disease Development Deal.NEWS9: Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates.NEWS10: Comparing Dividends and Interest Expenses for GILD and ABBV.NEWS11: Voyager Therapeutics stock soars after AbbVie collaboration potentially valued at over $1 billion.NEWS12: AbbVie and Voyager Therapeutics Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies.NEWS13: GILD or ABBV: Which Is Controlling Its Expenses Better?.NEWS14: What Pharma Investors Need to Know About Pfizer's Latest Disaster.NEWS15: What Pharma Investors Need to Know About Pfizer's Latest Disaster.NEWS16: What Pharma Investors Need to Know About Pfizer&apos;s Latest Disaster.
2019-02-25: NEWS1: Technician says it's time to fade the biotech rally.NEWS2: Pharma CEOs to face tough questions about skyrocketing drug prices.NEWS3: Factbox: Pharma company executives to testify at U.S. Senate drug price hearing.NEWS4: Big Pharma to testify in Senate drug pricing hearing.NEWS5: The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie.NEWS6: The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie.NEWS7: Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat.NEWS8: Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat.NEWS9: Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat.NEWS10: AbbVie Extends Deal With Voyager to Make Parkinson's Drugs.NEWS11: AbbVie Extends Deal With Voyager to Make Parkinson's Drugs.NEWS12: The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie.NEWS13: AbbVie to Showcase Scientific Innovation and Research Advancements Across Dermatology Portfolio at 2019 AAD Annual Meeting.NEWS14: AbbVie Extends Deal With Voyager to Make Parkinson's Drugs.

Answer: Rise